Full Press Release Details
Adagene Announces Poster Presentations of Clinical
Antibody Programs at ESMO Immuno-Oncology Congress 2021
SAN DIEGO and SUZHOU, China, November 22, 2021 - Adagene
Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the
discovery and development of novel antibody-based immunotherapies, today announced two poster presentations featuring clinical data for
its anti-CD137 agonist, ADG106, and anti-CTLA-4 monoclonal antibody, ADG116, at the European Society for Medical Oncology Immuno-Oncology
Congress (ESMO-IO) 2021.
conference abstracts are expected to be published on the ESMO-IO website on Thursday, December 2, 2021 and posters
available on Monday, December 6, 2021 in advance of the hybrid meeting being held virtually and in Geneva, Switzerland from
December 8 to 11, 2021.
clinical data from two of our ongoing NEObody clinical programs showcase the importance of our pioneering approach to target
a unique epitope and reflect the dynamic interactivity between an antibody and antigen," said Peter Luo, Ph.D., Co-founder, Chief
Executive Officer and Chairman of Adagene. "The pharmacodynamic biomarker findings from our ongoing ADG106 trial with the anti-PD-1
toripalimab reinforce the potential synergistic combination for strong T-cell activation. For our novel anti-CTLA-4 program, data from
the ongoing dose escalation of ADG116 monotherapy support the robust safety profile and dose dependent T-cell activation in both hot and
cold tumors, suggesting potential clinical benefit following our translational studies. Each of these analyses highlights the promise
of our tailor-made programs to achieve the fine balance between safety and efficacy - thereby unlocking the full value of some of
the most promising yet challenging immuno-oncology targets today."
Details for the poster presentations during ESMO-IO 2021 include:
Presentation Number: 43P
Date: Monday, December 6, 2021
Time: 12:00 Central European Time
Presentation Number: 137P
Date: Monday, December 6, 2021
Time: 12:00 Central European Time
and ADG116 programs use Adagene's innovative NEObody technology, which enables targeting of unique and highly conserved
epitopes against a broad range of antigens. These species cross-reactive antibodies not only have the potential to reveal new biological
functions of the targets, but also facilitate preclinical studies using various immune intact animal models, resulting in high fidelity
translation from preclinical to clinical studies. The company is also developing an anti-CTLA-4 antibody, ADG126, using its SAFEbody
precision masking technology.
Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development
of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel
antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody ,
SAFEbody , and POWERbody technologies, Adagene's highly differentiated pipeline features novel immunotherapy programs.
Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the
vanguard of science.
more information, please visit: https://investor.adagene.com.
Safe Harbor Statement
This press release contains forward-looking statements, including statements
regarding the potential implications of clinical data for patients, and Adagene's advancement of, and anticipated clinical activities,
clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from
those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene's
ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support
further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding
regulatory approval of Adagene's drug candidates; Adagene's ability to achieve commercial success for its drug candidates,
if approved; Adagene's ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene's
reliance on third parties to conduct drug development, manufacturing and other services; Adagene's limited operating history and
Adagene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug
candidates; Adagene's ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations,
and the impact of the COVID-19 pandemic on Adagene's clinical development, commercial and other operations, as well as those risks
more fully discussed in the "Risk Factors" section in Adagene's filings with the U.S. Securities and Exchange Commission.
All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be